ANGLE looks to change the game for cancer detection


() () has hailed the full De Novo submission of its Parsortix system to the US Food and Drug Administration (FDA) in 2020 as “a watershed moment” for the company and its goal to achieve the first-ever FDA clearance for a system to harvest cancer cells from patient blood for analysis.

In its results for the year to December 31, the biopsy specialist also noted that an ovarian cancer clinical verification study in progress with a leading US cancer centre, headline results from which are expected in the fourth quarter of 2021.

Meanwhile, ANGLE said post-year end it has launched clinical labs in the UK and US and initiated a global pharma services business, adding that it also signed its first large-scale pharma services contract with an oncology-focused pharma customer utilising the Parsortix system.

Looking to the numbers for the year, the company reported revenues of GBP0.8mln, up from GBP0.6mln in 2019, while losses for the year were GBP11.6mln reflecting planned investments, compared to a loss of GBP7.6mln in the prior year.


Please enter your comment!
Please enter your name here